The case for & against
Bull & Bear analysis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology firm that specializes in discovering and developing innovative medicines for serious diseases, particularly in the fields of immunology and oncology. The company is prominently noted for its pioneering products, such as Dupixent, which addresses chronic conditions, demonstrating strong sales across multiple therapeutic areas. With a robust pipeline and ongoing advancements, Regeneron seeks to expand its market presence while navigating competitive dynamics within the biopharmaceutical landscape.
Bull says
- ↑Q1 2026 revenues $3.6B (+19% YoY); Dupixent net sales $4.9B (+31% YoY).
- ↑Pipeline holds ~45 candidates; management expects ≥4 FDA approvals this year.
- ↑$15.8B cash balance; Q1 free cash flow $848M; $3B share buyback announced.
- ↑Dupixent first-in-class label expansions could address 4M US patients.
- ↑High earnings yield, solid profitability and reasonable leverage risk underpin quality.
- ↑Adapting pricing strategy and partnerships to counter competitive pressures.
Bear says
- ↓FDA review delay for ILEA-HD pre-filled syringe may push back launch.
- ↓Heavy reliance on Dupixent heightens risk from biosimilar and price cuts.
- ↓ILEA net sales declined YoY amid Avastin competition and affordability issues.
- ↓Negative growth momentum and downward earnings revisions may damp sentiment.
- ↓Elevated short interest signals investor skepticism and potential volatility.
- ↓Weak institutional ownership and marginal dividend yield raise shareholder concerns.
Investment themes with REGN
Genetic and drug innovations driving medical breakthroughs
Products and services targeting weight management
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Regeneron performed well in the first quarter, highlighted by double-digit growth on both the top and bottom line.
- First quarter 2026 total revenues grew 19% from the prior year to 3.6 billion, driven by higher Sanofi collaboration revenue, as well as strong growth in net sales of ILEA HD in the US and Libtyo globally.
- First quarter diluted net income per share grew 15% to $9.47 on net income of 1 billion.
Bear points
- Our GAAP gross margin was 76%, which was negatively impacted by costs incurred due to a temporary interruption in bulk manufacturing at our Limerick, Ireland site.
- As a result, we anticipate our GAAP gross margin will continue to be negatively impacted in the second quarter as production returns to normal levels.
- ILEA's U.S. net sales were $473 million, representing a 36% year-over-year decline.